Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03837509
Title INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Incyte Corporation
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ESP | DEU


No variant requirements are available.